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Introduction
This paper describes 
three health programs 
that I've been fortunate 
to be involved in as
Program Manager over the
past 7 years - the 'Umoona
Kidney Project', the 
national 'QAAMS' Program
for point-of-care HbA1c
testing and the 'Point-of-
Care in Aboriginal Hands'
Program. The common 
feature these models share
is the use of point-of-care
technology for the 
early detection and/or 
management of chronic
diseases (renal disease,
diabetes and cardiovascular 
disease). The primary
focus of each program has
been the rural and remote
Aboriginal Community
Controlled Health Service
(ACCHS) sector, because
these three chronic 
diseases account for a
huge burden of morbidity
and mortality in 
Aboriginal Australians.  
X
Most laboratory people think of a point-of-care testing (POCT) model that is
hospital-based, has direct connectivity with the laboratory and the laboratory
being in full control of the service. The models described in this paper are 
different because they function outside the 'comfort zone' of the hospital base,
with the Aboriginal community and their associated health service driving the
model. The point-of-care challenge in this context is to develop 
quality-assured, sustainable and clinically effective models for the community
setting.
POCT has several advantages specific to the Aboriginal health care setting.1
Through appropriate training, Aboriginal Health Workers can perform POCT
on-site, thereby empowering them to take greater responsibility for the health
of their own community members. Immediate availability of result means that
the Aboriginal patient doesn't have to come back for a followup visit, 
something that may often be very difficult to organise in the Aboriginal 
community setting due to other social and cultural priorities taking precedent
over health matters. By conducting the tests on-site, ownership and control of
health information remains with the community, a factor crucial to the 
acceptance and success of Indigenous health programs worldwide. Each of the
working models described is based on the four fundamental elements: 
continuing education, training, quality management and ongoing support for
point-of-care technology.
The Umoona Kidney Project 
The Umoona Kidney Project was a partnership between the Umoona
Aboriginal community at Coober Pedy in South Australia's far north (850 km
from Adelaide) and the Renal Units at Flinders Medical Centre and Women's
and Children's Hospital, Adelaide, South Australia.2 The primary focus of the
Umoona Kidney Project was a voluntary (or opportunistic) renal disease risk
assessment and management program for the 400-plus adults and children in
the community. 
Above Left: Aboriginal health worker Richard Jones conducting a POC risk assessment on Elizabeth
Taylor at the Port Lincoln Aboriginal Health Service, West Coast, SA.  Above Right: Aboriginal health
worker Sandy Wilson and Mark Shephard discussing POC results with a patient from Hack's Point,
near Meningie in the Coorong region of South Australia. 
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The Bayer DCA 2000 was used for
measurement of urine albumin:
creatinine ratio, or ACR, as 
the cornerstone of both the 
risk assessment and clinical 
management arms. Prior to the
commencement of the program, the
Adelaide team spent six months 
of groundwork talking to the 
community, holding information
forums, demonstrating all aspects
of POCT and discussing the ACR
test.
The overall risk factor profile of the
158 adults assessed (which 
represented approximately 65% of
the adults in the community)
showed 42% of the people had 
high blood pressure, 24% 
had diabetes, 19% had persistent 
microalbuminuria and 9% macroalbuminuria. Thirty-five people were 
identified as being at risk for renal disease and offered the ACE inhibitor
Coversyl (Servier Laboratories, Australia) which resulted in a sustained and 
statistically significant drop in blood pressure to normal levels, as well as a 
stabilisation of renal function, with mean ACR of the group (monitored using the
DCA 2000) falling from 17 to 12 mg/mmol (p=0.09, paired t-test). (Table 1). 
Across two years of continuous field testing (n=46) the DCA 2000 exhibited
a precision base (coefficient of variation, CV%) of 6.9 and 3.6% for urine
albumin (for Bayer QCs with concentrations of 36 and 208 mg/L respectively),
3.2 and 4.1% for creatinine (9 and 36 mmol/L) and 6.7% and 5.3 % for urine
ACR (ratios of 4.1 and 5.8 mg/mmol). These are well within precision goals
of 10%, 6% and 12% for urine albumin, creatinine and ACR (which can be
derived from biological variation and other international consensus data on
performance criteria).
The Umoona Community evaluated the program through a survey conducted
by community elders. By all criteria, the community expressed a high level of
satisfaction with the program and the use of POCT (with a greater than 90%
satisfaction rating being recorded for all questions). In December 2000, the
program was handed over to the Umoona Community as a self-sustaining 
Table 1. Reduction in Renal and Cardiovascular Risk Two Years After Commencing Coversyl.
Pre-Coversyl Post-Coversyl
Marker Measure/Matrix Baseline 2 Years P-Value*
Units Mean (+/-SEM) Mean (+/-SEM)
Blood Pressure
Standing Systolic mmHg 151 (±3) 137 (±3) <0.0001
Diastolic mmHg 92 (±2) 84 (±2) <0.0001
Lying Systolic mmHg 147 (±3) 131 (±3) <0.0001
Diastolic mmHg 94 (±2) 84 (±2) <0.0001
Albumin:
Creatinine  
Ratio (ACR) Urine mg/mmol 16.5 (±3.9) 12.0 (±2.8) ns
Potassium Plasma mmol/L 4.0 ±0.1) 4.0 (±0.1) ns
Urea Plasma mmol/L 4.9 (±0.3) 5.1 (±0.3) ns
Creatinine Plasma mmol/L 0.081 (±0.003) 0.077 (±0.003) ns
Glomerular Filtration Rate (GFR)** mLs/min 110 (±5) 118 (±8) 0.019
* p < 0.05 is significant; ns = not significant.
** Calculated GFR by Cockcroft DW and Gault MH. 
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activity fully integrated into the
health service infrastructure. Both
the South Australian Government's
Department of Human Services
Renal and Urology Services
Implementation Plan 2000-2011
and the Statewide Iga Warta
Aboriginal Renal Disease Summit,
1999 endorsed the Umoona model
for expansion to other Aboriginal
communities in rural and remote
South Australia.
One of the most pleasing aspects
of the Umoona Kidney Project was
that POCT became a focal point
for raising community awareness
about renal disease. We were able
to build on the trust and respect
gained from the renal program and
conduct a number of other community
activities around related health
issues and health promotion. These
included developing a nutrition
training program for Umoona's
Aboriginal Health Workers, 
staging a poster competition for
the children at the Coober Pedy
Area School about healthy foods
and holding education days at the
school about kidney health and the
importance of good food 
(sponsored by the Australian
Kidney Foundation).  A bush 
tucker trip was also conducted
with the Umoona Community
Elders for the school children,
where the children were taught
how to dig for witchetty grubs, 
collect other bush foods and cook
kangaroo.
The National 'QAAMS' Program for Point-of-Care HbA1c testing 
The 'QAAMS' Program, or Quality Assurance for Aboriginal Medical
Services as it is known, arose from a recommendation of the National
Diabetes Strategy in 1998, commenced as a pilot in June 1999 and, is now
fully integrated into mainstream Aboriginal health care in Australia.3 Since its
inception, the program has been a collaborative partnership between a number
of groups including the Office for Aboriginal and Torres Strait Islander Health
(OATSIH), the Diagnostics and Technology Branch within the Australian
Government's Department of Health and Ageing, the National Aboriginal
Community Controlled Health Organisation (NACCHO), the RCPA Quality
Assurance Programs Pty Ltd and the Community Point-of-Care Services Unit. 
The chronic disease focus of the QAAMS program is the management of
established diabetes. Over 2300 Aboriginal patients with diabetes are involved
in the program, which is being conducted at 50 Commonwealth and
State/Territory funded Aboriginal Medical Services around Australia. These
sites cover urban, rural and remote locations and encompass every state and
Territory in Australia (Figure 1). At each site Aboriginal Health Workers
measure HbA1c using the Bayer DCA 2000. A Quality Assurance Program
(called QAAMS) to constantly monitor the analytical performance of all the
DCA 2000 instruments in the field was developed collaboratively by the
Community Point-of-Care Services unit at Flinders University and the RCPA
Quality Assurance Programs Pty Ltd. This is the first program of this type to
be developed for Indigenous people anywhere in the world.
“One of the most 
pleasing aspects of the
Umoona Kidney Project 
was that POCT became 
a focal point for raising 
community awareness
about renal disease. We
were able to build on the
trust and respect gained
from the renal program and
conduct a number of other
community activities around
related health issues and
health promotion.”
Figure 1. Map showing general location of QAAMS Participants in 2003.
Above: Mark Shephard conducting training for participants in the QAAMS ACR Program.
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Each QAAMS participant is provided with an annual kit of quality assurance
samples for testing (with 2 samples to be tested per month), a single-page
result sheet, and a monthly summary report with a graphical result format
similar to, but more simplified than, that provided for laboratories. Each site
has its own Community Number to ensure confidentiality of results. Eight 
six-monthly testing cycles have been completed over the four years from July
1999 to July 2003.  Participation rate has averaged 87% (range 81-93%)
across all eight testing cycles with over 3500 quality assurance results
returned during this time. The percentage of results considered acceptable has
averaged 83% (range 81 to 86%), using limits for acceptable performance that
are the same as those for the laboratory-based Glycohaemoglobin Program
run by the RCPA Quality Assurance Programs Pty Ltd (±5%). Across the past
five testing cycles in particular, the median precision base (CV%) achieved by
Aboriginal medical services in the QAAMS program has been equivalent to
that achieved by 75 laboratory-based DCA 2000 users registered in the
Glycohaemoglobin program (Table 2). As the table also shows, the precision
achieved by Aboriginal medical services has been very consistent over time
and approaches the 3% mark, which is the desired performance for 
monitoring of people with diabetes. 
In March 2001, NACCHO conducted an independent evaluation of the first
18 months of the QAAMS program. The Executive Summary of this report
stated that the use of the DCA point-of-care technology represented a major
opportunity to better care for and manage Aboriginal clients with diabetes
within the community setting, while the ability of POCT to generate rapid
results served as a catalyst to enhance patient self-management. The 
summary concluded the DCA 2000's simplicity of use led to high levels of
acceptance by Aboriginal health workers nationally, with nearly two-thirds of
services expressing the view that it had raised the self esteem of their health
workers.  Importantly, the sense of community control was enhanced as a
result of diabetes management becoming more focused within Aboriginal
medical services.
Table 2. Comparative Precision Base Over Last Five Testing Cycles: Aboriginal Community Controlled Health
Services (ACCHS) versus Laboratories using the Bayer DCA 2000.
Cycle Period
Program Type of Service Jan to June July to Dec Jan to June July to Dec Jan to July 
2001 2001 2002 2002 2003
QAAMS ACCHS 3.7 4.1 3.9 3.4 3.8
Glycohaemoglobin Laboratories 3.4 4.1 3.7 3.5 3.6
* Coefficient of variation (CV%) is calculated by dividing the standard deviation by the mid-point of the service’s
range of concentrations, expressed as a percentage. The standard deviation is the error of the estimate Sy.x and
represents the average standard deviation across the range of concentrations analysed.
To further enhance the sustainability
of the QAAMS HbA1c program, a
Medicare rebate is now available
for participating sites and an annual
workshop has been held since 2001.
These workshops have now become
a key feature of the QAAMS 
calendar. The meetings are very
interactive, with significant 
opportunities for retraining and 
networking. All participants now
undergo competency assessment
and certification (in both practical
and theoretical elements of the 
program) at the Workshop. A new
QAAMS program for ACR 
testing on the DCA 2000 
commenced in 2003 and involves
30 ACCHS. 
“Over 2300 Aboriginal
patients with diabetes are
involved in the HbA1c 
program, which is being
conducted at 50
Commonwealth and
State/Territory funded
Aboriginal Medical 
Services around Australia.”
Beryl Mazzachi, medical scientist from the
Community Point-of-Care Services unit,
training Aboriginal health workers Barbara
White (left) and Erica Cox at the Broome
Aboriginal Medical Service, Kimberley, WA. 
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The Point-of-Care in Aboriginal
Hands Program 
The Point-of-Care in Aboriginal
Hands program, which 
commenced in mid 2001, is 
a partnership between the
Community Point-of-Care
Services unit and four rural and
remote Aboriginal health services
at Port Lincoln, the Riverland and
Meningie in South Australia and at
Kalgoorlie in Western Australia.4
Education, training and quality
management of POCT again
underpin the program and the local
Aboriginal Health Worker(s) is
responsible for the day-to-day
operation of the point-of-care 
technology. 
However the Point-of-Care in
Aboriginal Hands program differs
from the other models described in
several fundamental ways. Firstly
it has a greater local community
focus with local medical officers
and/or Medical Directors undertaking
all clinical management at each
health service.  Secondly, the 
program has a broader chronic 
disease focus that looks at the early
detection, risk assessment and
management of diabetes, renal 
disease and cardiovascular disease
collectively rather than having a
single disease focus for example
renal for the Umoona project or
diabetes for the QAAMS HbA1c
program. Finally, there is wider use
of POCT with  Aboriginal Health
Workers trained to use the Bayer
DCA 2000 for both HbA1c and
urine ACR testing and the
Cholestech LDX lipid analyser.
While most of the point-of-care
risk assessments are conducted in
the clinic setting, the opportunity is
taken whenever possible to conduct 
field-testing outside the clinic. For example, testing has been carried out at
such diverse locations as a local eco-tourism centre, a TAFE (adult education)
College, and in a tin shed at the Pt Lincoln Aboriginal Women's Centre (an
event which was also linked with a nutrition health promotion activity). In the
Riverland, a bus has been purchased and renovated to provide a mobile POCT
service throughout the Riverland region (with risk assessment also linked to
an eye check for people with diabetes through a separate program). 
These examples really show the flexibility and versatility of POCT in the
community setting.
Across all four participating sites over 600 chronic disease risk assessments
have been performed by POCT. Diabetes is extremely prevalent, there is a
large incipient pool of renal disease, with rates of microalbuminuria ranging
from 19 to 26% in the general community and elevated lipids are very 
common. An example of the risk assessment profile found at one community
is shown in Figure 2. For clinical management flow charts for POCT have
been developed in collaboration with each community, based on best practice 
evidence and input of the local clinicians. The frequency of follow-up testing
is determined by diabetes, blood pressure, microalbumin and lipid status. At
Port Lincoln a subset of 29 patients with diabetes have shown a mean decrease
in HbA1c of 0.4% after a year on POCT and managed care planning.
All sites are now enrolled in both national QAAMS programs - for HbA1c and
urine ACR - and they conduct on-site internal quality control testing, the
results of which are immediately faxed to and managed by the Flinders'
Community Point-of-Care Services unit. There is also monthly communication
between the unit and each participating site around a quality management
checklist. Quarterly on-site field visits are also conducted by the Flinders'
team. Table 3 details the analytical performance achieved by each site for
QAAMS testing in the most recent cycle. These results again clearly demonstrate
that point-of-care testing can be carried out to a high level of analytical 
competency by Aboriginal Health Workers, provided they are supported by a
quality management framework comprising on-going education, training and
participation in structured quality management programs. 
Figure 2. Chronic Disease Risk Assessment Profile at one community.
Left : Conducting POC chronic disease 
risk assessments in a tin shed at the Port
Lincoln Aboriginal Women's Centre. 
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Table 3. Median Precision Achieved for QAAMS HbA1c and Urine ACR
Testing by the Four Sites Participating in the Point-of-Care in Aboriginal
Hands Program
HbA1c Urine ACR
Site Median Precision Median Precision
Precision Goal Precision Goal
(CV%) (CV%) (CV%) (CV%)
1 3.2% 3% 4.3% 12%
2 3.1% 5.1%
3 3.1% N/A*
4 2.9% 5.0%
* Data is not available for the Urine ACR Program for Site 3. 
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training Maxine Gosam (Innisfail, 
North Queensland) and Jacqueline
Freeburn (Grafton, NSW) in how to 
conduct quality assurance testing on the
Bayer DC 2000 point-of-care analyser.
